CGRP (Calcitonin Gene-Related Peptide): Vasodilation Research, Migraine Mechanisms & Antagonist Development

Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide produced by alternative splicing of the calcitonin gene (CALCA). It exists in two isoforms — α-CGRP, predominantly expressed in sensory neurons of the trigeminal and dorsal root ganglia, and β-CGRP, found mainly in the enteric nervous system. α-CGRP is the isoform that dominates vascular and pain research.

This extraordinary potency made CGRP one of the first neuropeptides identified as a direct link between the sensory nervous system and vascular function.

Receptor Pharmacology: The CLR/RAMP1 Complex

CGRP does not bind a conventional single-protein receptor. Instead, it signals through a heterodimeric complex consisting of the calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1). Without RAMP1, CLR cannot traffic to the cell surface or bind CGRP with high affinity. This requirement for a co-receptor makes the CGRP system pharmacologically unique and explains why developing selective antagonists proved challenging for decades.

In sensory neurons, CGRP signaling also modulates pain sensitization pathways, lowering activation thresholds and amplifying nociceptive transmission. This dual vascular-neural action is central to its role in migraine pathophysiology.

CGRP and Migraine: From Observation to Mechanism

The connection between CGRP and migraine was established through a series of elegant experiments in the 1990s and 2000s. Goadsby and Edvinsson demonstrated that CGRP levels in jugular venous blood rise sharply during migraine attacks. And CGRP receptor antagonists abort these induced attacks.

The mechanistic picture that emerged places CGRP at the center of the trigeminovascular system — the neural circuit connecting trigeminal sensory fibers to meningeal blood vessels.

What made this discovery transformative was its mechanistic specificity.

Two classes of anti-CGRP agents have reached the clinic. Monoclonal antibodies — erenumab (targeting the CLR/RAMP1 receptor), fremanezumab, galcanezumab, and eptinezumab (targeting the CGRP ligand) — provide sustained CGRP pathway blockade with monthly or quarterly injections.

Small-molecule CGRP receptor antagonists, called gepants, offer oral alternatives. Ubrogepant, rimegepant, and atogepant are approved for acute or preventive migraine use.

The existence of both antibody and small-molecule approaches targeting the same pathway provides researchers with complementary tools for studying CGRP biology — long-acting depot blockade versus acute, reversible antagonism.

CGRP’s role extends beyond headache neurobiology.

Research Frontiers

The CGRP field in 2026 sits at the intersection of neuroscience, vascular biology, and immunology — a rich territory for peptide researchers.

Disclaimer: This content is intended for research purposes only and is not meant to constitute medical advice.